A Phase 1 interventional study of AZD9977, oral suspension and Placebo, oral suspension in Safety, Tolerability and Pharmacokinetics, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-28.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be a randomized, single-blind, placebo-controlled first-in-human study in healthy male subjects to assess the safety, tolerability and pharmacokinetics of single ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along the gastro-intestinal tract will be investigated using the IntelliCap® system in a non-randomized, open-label, fixed-sequence design. The study will be performed at a single study centre.
This study will be a randomized, single-blind, placebo-controlled first-in-human study in healthy male subjects to assess the safety, tolerability and pharmacokinetics of single ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along the gastro-intestinal tract will be investigated using the IntelliCap® system in a non-randomized, open-label, fixed-sequence design with oral solution as reference. The study will be performed at a single study centre.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Optional: Provision of signed and dated written informed consent for genetic research.
If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.
Exclusion Criteria:
Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:
PR (PQ) interval prolongation > 240ms; intermittent second or third degree atrioventricular (AV) block, or AV dissociation.
Wenckebach block while asleep is not exclusive.
Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms.
QRS > 110 ms but \< 115 ms are acceptable if there is no evidence of ventricular hypertrophy or pre-excitation.
Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of dosing in Part A or the first dose of AZD9977 in Part B in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.
Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.
Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
In addition, any of the following is regarded as a criterion for exclusion from the genetic research:
Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Criteria applicable to Part B only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
Drug: AZD9977, oral suspension
In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
Drug: Placebo, oral suspension
In Part B, of oral solution of AZD9977 will be used as reference
Drug: AZD9977, oral solution
Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
Matching placebo
AZD9977, single dose of oral solution in Part B as reference
Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 4 days, i.e. on the day before each dosing and for 24 hours after each dosing
Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis
To assess the safety and tolerability of single ascending doses of AZD9977
Time frame: For up to 45 days, i.e. from Screening to Follow-up
Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity.
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
Time frame: Pre-dose and post-dose upto 48 hrs
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t)
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
Time frame: Pre-dose and post-dose upto 48 hrs
Observed Maximum Concentration (Cmax)
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
Time frame: Pre-dose and post-dose upto 48 hrs
Time to Maximum Observed Plasma Concentration (t Max)
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
Time frame: Pre-dose and post-dose upto 48 hrs
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz)
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
Time frame: Pre-dose and post-dose upto 48 hrs
Apparent Clearance (CL/F)
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
Time frame: Pre-dose and post-dose upto 48 hrs
Apparent Volume of Distribution (Vz/F)
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
Time frame: Pre-dose and post-dose upto 48 hrs
Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)]
To assess urine pharmacokinetic parameters following single ascending doses of AZD9977
Time frame: Pre-dose and post-dose upto 48 hrs
Fraction Excreted Unchanged in Urine[Fe (0-48)]
To assess percentage of the total drug excreted in the urine that was unchanged following single ascending doses of AZD9977
Time frame: Pre-dose and post-dose upto 48 hrs
Renal Clearance of Drug From Plasma [CLR (0-48)]
To assess urine pharmacokinetic parameters following single ascending doses of AZD9977
Time frame: Pre-dose and post-dose upto 48 hrs
This study was conducted at PAREXEL International, Early Phase Clinical Unit London, United Kingdom.
| Milestone | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 16 | 6 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 8 |
| Completed | 16 | 6 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Failure of intellicap error | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
To assess the safety and tolerability of single ascending doses of AZD9977
| percentage of participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events | 43.8 | 16.7 | 33.3 | 33.3 | 20.0 | 33.3 | 0 | 33.3 | 16.7 | 37.5 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of Participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Pulse Rate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Trends in 12-lead Electrocardiograms | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of Participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Number of Participants With Clinically Significant Trends in Cardiac Telemetry | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of Participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing the Number of Subjects With Adverse Events | 7 | 1 | 2 | 2 | 1 | 2 | 0 | 2 | 1 | 3 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of Participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Blood Pressure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Hematology | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Clinical Chemistry | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess the safety and tolerability of single ascending doses of AZD9977
| Number of participants | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of AZD9977 by Assessing Number of Participants With Clinically Significant Changes in Urinalysis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
| h.nmol/L | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Intellicap Device (Part B) | Oral Suspension (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) From Zero Extrapolated to Infinity. | 514.4 ± 13.4 | 2473 ± 24.5 | 9576 ± 51.9 | 23810 ± 33.7 | 36210 ± 28.5 | 38060 ± 37.2 | 98910 ± 29.7 | 105700 ± 30.5 | 2256 ± 32.6 | 3294 ± 32.9 |
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
| h.nmol/L | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Intellicap Device (Part B) | Oral Suspension (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte concentrationAUC(0-t) | 482.7 ± 14.9 | 2429 ± 24.7 | 9419 ± 52.2 | 23470 ± 34.2 | 35650 ± 26.0 | 34190 ± 16.1 | 82720 ± 35.6 | 93750 ± 37.5 | 1754 ± 38.1 | 3136 ± 31.5 |
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
| nmol/L | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Intellicap Device (Part B) | Oral Suspension (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|
| Observed Maximum Concentration (Cmax) | 201.6 ± 27.7 | 952.0 ± 20.9 | 3367 ± 41.3 | 5966 ± 40.6 | 7243 ± 27.7 | 7149 ± 17.2 | 14310 ± 29.1 | 16700 ± 29.2 | 161.2 ± 36.8 | 790.9 ± 22.9 |
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
| Hour (h) | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Intellicap Device (Part B) | Oral Suspension (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Maximum Observed Plasma Concentration (t Max) | 0.50 (0.50 to 1.08) | 0.99 (0.50 to 1.02) | 0.50 (0.50 to 1.02) | 1.00 (0.48 to 1.00) | 0.88 (0.38 to 1.50) | 0.75 (0.50 to 1.00) | 3.51 (3.50 to 4.50) | 3.74 (2.50 to 4.50) | 4.02 (1.98 to 5.52) | 0.75 (0.23 to 1.50) |
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
| Hour (h) | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Intellicap Device (Part B) | Oral Suspension (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|
| Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz) | 1.741 ± 0.1753 | 1.755 ± 0.2923 | 7.161 ± 4.397 | 10.00 ± 1.933 | 9.618 ± 3.412 | 22.99 ± 6.527 | 21.17 ± 12.18 | 21.68 ± 3.495 | 11.60 ± 6.081 | 6.145 ± 3.365 |
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
| L/h | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Intellicap Device (Part B) | Oral Suspension (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Clearance (CL/F) | 24.52 ± 3.391 | 25.89 ± 5.546 | 28.46 ± 11.08 | 21.84 ± 5.812 | 28.49 ± 7.392 | 54.34 ± 19.16 | 20.99 ± 6.683 | 29.38 ± 8.430 | 45.97 ± 13.03 | 31.82 ± 10.79 |
To assess plasma pharmacokinetic parameters following single ascending doses of AZD977
| L | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Intellicap Device (Part B) | Oral Suspension (Part B) |
|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) | 61.50 ± 9.724 | 64.52 ± 13.40 | 266.1 ± 180.6 | 315.8 ± 111.9 | 401.9 ± 180.0 | 1712 ± 123.7 | 652.5 ± 414.0 | 897.0 ± 210.6 | 720.1 ± 348.2 | 269.4 ± 142.2 |
To assess urine pharmacokinetic parameters following single ascending doses of AZD9977
| nmol | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) |
|---|---|---|---|---|---|---|---|---|
| Cumulative Amount of Unchanged Drug Excreted Into Urine [Ae (0-48)] | 2491 ± 213.4 | 12440 ± 2818 | 59700 ± 21910 | 122800 ± 27020 | 189700 ± 46420 | 178600 ± 32530 | 428600 ± 93430 | 503400 ± 132300 |
To assess percentage of the total drug excreted in the urine that was unchanged following single ascending doses of AZD9977
| Percentage | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) |
|---|---|---|---|---|---|---|---|---|
| Fraction Excreted Unchanged in Urine[Fe (0-48)] | 19.90 ± 1.705 | 19.88 ± 4.502 | 23.84 ± 8.750 | 24.53 ± 5.396 | 18.94 ± 4.635 | 8.917 ± 1.624 | 21.40 ± 4.664 | 16.75 ± 4.402 |
To assess urine pharmacokinetic parameters following single ascending doses of AZD9977
| L/h | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) |
|---|---|---|---|---|---|---|---|---|
| Renal Clearance of Drug From Plasma [CLR (0-48)] | 5.018 ± 0.5818 | 5.061 ± 1.195 | 6.114 ± 1.533 | 5.230 ± 1.028 | 5.371 ± 0.6880 | 5.700 ± 1.097 | 5.274 ± 0.9817 | 5.319 ± 0.5086 |
Collected over SAEs will be collected from the signing of informed consent and AEs from randomization until the final follow-up visit in Part A, and from first dosing until the final follow-up visit in Part B.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A- Placebo | — | 0/16 (0%) | 7/16 (43.8%) |
| Part A - 5 mg AZD9977 | — | 0/6 (0%) | 1/6 (16.7%) |
| Part A - 25 mg AZD9977 | — | 0/6 (0%) | 2/6 (33.3%) |
| Part A - 100 mg AZD9977 | — | 0/6 (0%) | 2/6 (33.3%) |
| Part A - 200 mg AZD9977 | — | 0/5 (0%) | 1/5 (20%) |
| Part A - 400 mg AZD9977 | — | 0/6 (0%) | 1/6 (16.7%) |
| Part A - 800 mg AZD9977 | — | 0/5 (0%) | 0/5 (0%) |
| Part A - 800 mg AZD9977 (Split Doses) | — | 0/6 (0%) | 2/6 (33.3%) |
| Part A - 1200 mg AZD9977 (Split Doses) | — | 0/6 (0%) | 1/6 (16.7%) |
| Part B | — | 0/8 (0%) | 3/8 (37.5%) |
| Event | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B |
|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/16 | 0/6 | 0/6 | 0/6 | 0/5 | 0/6 | 0/5 | 0/6 | 1/6 | 2/8 |
| DizzinessNervous system disorders | 1/16 | 1/6 | 1/6 | 0/6 | 1/5 | 0/6 | 0/5 | 0/6 | 0/6 | 0/8 |
| HeadacheNervous system disorders | 1/16 | 0/6 | 0/6 | 1/6 | 0/5 | 0/6 | 0/5 | 0/6 | 0/6 | 1/8 |
| BackpainMusculoskeletal and connective tissue disorders | 0/16 | 0/6 | 0/6 | 1/6 | 0/5 | 1/6 | 0/5 | 0/6 | 0/6 | 0/8 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/5 | 1/6 | 0/5 | 0/6 | 0/6 | 0/8 |
| Abdominal distensionGastrointestinal disorders | 0/16 | 0/6 | 1/6 | 0/6 | 0/5 | 0/6 | 0/5 | 0/6 | 0/6 | 0/8 |
| NauseaGastrointestinal disorders | 0/16 | 0/6 | 0/6 | 1/6 | 0/5 | 0/6 | 0/5 | 0/6 | 0/6 | 1/8 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/5 | 0/6 | 0/5 | 1/6 | 0/6 | 0/8 |
| PruritusSkin and subcutaneous tissue disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/5 | 0/6 | 0/5 | 1/6 | 0/6 | 0/8 |
| Feeling hotGeneral disorders | 0/16 | 0/6 | 0/6 | 0/6 | 0/5 | 0/6 | 0/5 | 1/6 | 0/6 | 0/8 |
| Age, Continuous(Years) | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 30 ± 6 | 32 ± 11 | 30 ± 9 | 36 ± 10 | 32 ± 10 | 33 ± 9 | 30 ± 6 | 32 ± 8 | 38 ± 11 | 35 ± 9 | 33 ± 9 |
| Sex/Gender, Customized(Participants) | Part A- Placebo | Part A - 5 mg AZD9977 | Part A - 25 mg AZD9977 | Part A - 100 mg AZD9977 | Part A - 200 mg AZD9977 | Part A - 400 mg AZD9977 | Part A - 800 mg AZD9977 | Part A - 800 mg AZD9977 (Split Doses) | Part A - 1200 mg AZD9977 (Split Doses) | Part B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | 16 | 6 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 8 | 70 |
The record gives a start of Jul 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD9977